Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
Diseases of the Musculoskeletal System
What is the purpose of this trial?
To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects.
- Ages40 years - 80 years
- Trial withRa Pharmaceuticals, Inc.
- Start Date07/01/2020
- End Date12/31/2020
- Last Updated07/15/2021
- Study HIC#2000026786